Details, Fiction and Clinical trial recruitment for ABBV-744 study
In Section A, participants will acquire distinctive doses and schedules of oral ABBV-744 pill to identify Harmless dosing routine. Further participants will be enrolled at the determined monotherapy dosign regimen. In Phase B, individuals will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members will